| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Blood | 80 | 2024 | 501 | 11.840 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 285 | 2024 | 7017 | 11.830 |
Why?
|
| Cord Blood Stem Cell Transplantation | 64 | 2023 | 372 | 11.360 |
Why?
|
| Graft vs Host Disease | 114 | 2024 | 2808 | 8.020 |
Why?
|
| Hematopoietic Stem Cells | 64 | 2019 | 1366 | 5.540 |
Why?
|
| Immunotherapy, Adoptive | 52 | 2024 | 1840 | 4.520 |
Why?
|
| Killer Cells, Natural | 34 | 2024 | 965 | 4.280 |
Why?
|
| Transplantation Conditioning | 87 | 2024 | 2368 | 4.250 |
Why?
|
| Hematologic Neoplasms | 47 | 2024 | 1955 | 3.950 |
Why?
|
| Multiple Myeloma | 43 | 2024 | 2281 | 3.500 |
Why?
|
| Transplantation, Homologous | 93 | 2024 | 3044 | 3.230 |
Why?
|
| Antigens, CD34 | 51 | 2024 | 639 | 3.130 |
Why?
|
| Leukemia, Myeloid, Acute | 80 | 2024 | 7263 | 3.120 |
Why?
|
| Transplantation, Autologous | 92 | 2024 | 2045 | 2.910 |
Why?
|
| T-Lymphocytes | 57 | 2024 | 3944 | 2.730 |
Why?
|
| Cyclophosphamide | 59 | 2024 | 3243 | 2.520 |
Why?
|
| Bone Marrow Transplantation | 47 | 2024 | 1757 | 2.180 |
Why?
|
| Busulfan | 33 | 2024 | 792 | 2.150 |
Why?
|
| Cell Separation | 29 | 2017 | 610 | 2.040 |
Why?
|
| Humans | 584 | 2024 | 270802 | 1.990 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 19 | 2023 | 1738 | 1.990 |
Why?
|
| Receptors, Antigen, T-Cell | 23 | 2024 | 1135 | 1.940 |
Why?
|
| Cytomegalovirus Infections | 16 | 2024 | 495 | 1.930 |
Why?
|
| Cell- and Tissue-Based Therapy | 16 | 2023 | 381 | 1.770 |
Why?
|
| Stem Cell Transplantation | 33 | 2023 | 1414 | 1.730 |
Why?
|
| Bone Marrow Purging | 13 | 2011 | 88 | 1.640 |
Why?
|
| Antigens, CD19 | 27 | 2024 | 584 | 1.610 |
Why?
|
| Myeloablative Agonists | 18 | 2022 | 386 | 1.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 99 | 2024 | 16669 | 1.600 |
Why?
|
| Unrelated Donors | 20 | 2024 | 321 | 1.590 |
Why?
|
| Adult | 271 | 2024 | 81997 | 1.560 |
Why?
|
| Cell Culture Techniques | 20 | 2018 | 574 | 1.550 |
Why?
|
| Histocompatibility Testing | 23 | 2024 | 487 | 1.520 |
Why?
|
| Cytomegalovirus | 18 | 2024 | 496 | 1.460 |
Why?
|
| Siblings | 7 | 2024 | 318 | 1.450 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2017 | 714 | 1.450 |
Why?
|
| Vidarabine | 31 | 2022 | 1383 | 1.420 |
Why?
|
| Middle Aged | 262 | 2024 | 90347 | 1.420 |
Why?
|
| Graft Survival | 25 | 2017 | 1082 | 1.410 |
Why?
|
| Dendritic Cells | 13 | 2021 | 1110 | 1.370 |
Why?
|
| Myelodysplastic Syndromes | 28 | 2024 | 3152 | 1.340 |
Why?
|
| HLA Antigens | 17 | 2024 | 594 | 1.310 |
Why?
|
| Aged | 179 | 2024 | 73382 | 1.210 |
Why?
|
| Fucose | 4 | 2016 | 58 | 1.210 |
Why?
|
| Female | 304 | 2024 | 148967 | 1.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 16 | 2020 | 2484 | 1.210 |
Why?
|
| Tissue Donors | 13 | 2024 | 815 | 1.150 |
Why?
|
| Recurrence | 53 | 2024 | 4877 | 1.140 |
Why?
|
| Cells, Cultured | 43 | 2021 | 5698 | 1.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 8 | 2021 | 205 | 1.120 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 13 | 2022 | 270 | 1.120 |
Why?
|
| Breast Neoplasms | 85 | 2018 | 16205 | 1.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 19 | 2022 | 770 | 1.070 |
Why?
|
| Antigens, CD | 24 | 2009 | 1419 | 1.070 |
Why?
|
| Male | 226 | 2024 | 128397 | 1.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 21 | 2024 | 2902 | 1.060 |
Why?
|
| Melphalan | 28 | 2023 | 875 | 1.050 |
Why?
|
| Transplantation, Haploidentical | 8 | 2024 | 159 | 1.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 14 | 2021 | 1020 | 1.000 |
Why?
|
| Young Adult | 88 | 2024 | 22225 | 0.980 |
Why?
|
| Immunotherapy | 15 | 2023 | 3557 | 0.970 |
Why?
|
| Lymphoma, B-Cell | 11 | 2024 | 929 | 0.970 |
Why?
|
| Adolescent | 95 | 2024 | 32743 | 0.940 |
Why?
|
| Blood Platelets | 5 | 2015 | 677 | 0.940 |
Why?
|
| Retrospective Studies | 114 | 2024 | 39832 | 0.910 |
Why?
|
| Antigen-Presenting Cells | 8 | 2021 | 286 | 0.910 |
Why?
|
| Neutrophils | 11 | 2017 | 873 | 0.870 |
Why?
|
| Remission Induction | 36 | 2024 | 3652 | 0.870 |
Why?
|
| Treatment Outcome | 100 | 2024 | 33741 | 0.850 |
Why?
|
| Th1 Cells | 4 | 2016 | 259 | 0.820 |
Why?
|
| BK Virus | 7 | 2020 | 126 | 0.820 |
Why?
|
| Heterocyclic Compounds | 5 | 2022 | 117 | 0.820 |
Why?
|
| Thrombocytopenia | 6 | 2022 | 870 | 0.790 |
Why?
|
| Cell Proliferation | 21 | 2021 | 7237 | 0.780 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 13 | 0.770 |
Why?
|
| Convalescence | 1 | 2021 | 23 | 0.760 |
Why?
|
| Common Cold | 1 | 2021 | 35 | 0.760 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2021 | 28 | 0.740 |
Why?
|
| Adoptive Transfer | 7 | 2022 | 431 | 0.740 |
Why?
|
| Allografts | 18 | 2024 | 686 | 0.730 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 7 | 2017 | 218 | 0.730 |
Why?
|
| Biological Products | 3 | 2023 | 319 | 0.730 |
Why?
|
| Hodgkin Disease | 13 | 2022 | 1485 | 0.720 |
Why?
|
| Disease-Free Survival | 53 | 2023 | 10260 | 0.720 |
Why?
|
| Hematopoiesis | 7 | 2015 | 601 | 0.720 |
Why?
|
| Antineoplastic Agents | 40 | 2023 | 14616 | 0.710 |
Why?
|
| Tacrolimus | 12 | 2023 | 347 | 0.700 |
Why?
|
| Cellular Reprogramming | 2 | 2024 | 202 | 0.690 |
Why?
|
| Lymphoma | 13 | 2024 | 1520 | 0.690 |
Why?
|
| Genetic Engineering | 3 | 2019 | 295 | 0.690 |
Why?
|
| Survival Rate | 50 | 2024 | 12527 | 0.680 |
Why?
|
| Bone Marrow | 24 | 2021 | 2438 | 0.680 |
Why?
|
| Antilymphocyte Serum | 9 | 2015 | 237 | 0.680 |
Why?
|
| Exosomes | 2 | 2019 | 255 | 0.670 |
Why?
|
| Survival Analysis | 49 | 2022 | 9290 | 0.660 |
Why?
|
| Leukemia | 12 | 2024 | 1719 | 0.660 |
Why?
|
| Immunosuppressive Agents | 19 | 2024 | 1431 | 0.660 |
Why?
|
| Thalidomide | 5 | 2017 | 595 | 0.660 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 212 | 0.640 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2024 | 980 | 0.640 |
Why?
|
| Neoplasms | 30 | 2024 | 15919 | 0.640 |
Why?
|
| Graft vs Leukemia Effect | 5 | 2016 | 107 | 0.630 |
Why?
|
| Platelet Transfusion | 4 | 2015 | 166 | 0.630 |
Why?
|
| Salvage Therapy | 15 | 2018 | 2122 | 0.620 |
Why?
|
| Lymphoma, Non-Hodgkin | 13 | 2023 | 1067 | 0.620 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2023 | 1655 | 0.620 |
Why?
|
| Mice | 58 | 2024 | 35597 | 0.620 |
Why?
|
| Bronchiolitis Obliterans | 3 | 2024 | 94 | 0.620 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2015 | 38 | 0.620 |
Why?
|
| Virus Diseases | 4 | 2016 | 392 | 0.610 |
Why?
|
| Coculture Techniques | 14 | 2020 | 628 | 0.600 |
Why?
|
| Bone Marrow Cells | 15 | 2014 | 968 | 0.600 |
Why?
|
| Hepatic Veno-Occlusive Disease | 4 | 2024 | 135 | 0.600 |
Why?
|
| Combined Modality Therapy | 55 | 2021 | 9039 | 0.600 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2022 | 1052 | 0.590 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2016 | 714 | 0.580 |
Why?
|
| Animals | 70 | 2024 | 62048 | 0.580 |
Why?
|
| CD3 Complex | 6 | 2024 | 320 | 0.580 |
Why?
|
| Polyomavirus Infections | 5 | 2020 | 147 | 0.580 |
Why?
|
| Neoplasm, Residual | 11 | 2023 | 1752 | 0.570 |
Why?
|
| Ficoll | 1 | 2016 | 6 | 0.570 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2016 | 2634 | 0.570 |
Why?
|
| Hematologic Diseases | 3 | 2016 | 255 | 0.560 |
Why?
|
| Lymphocyte Activation | 12 | 2019 | 1723 | 0.560 |
Why?
|
| Virus Activation | 6 | 2019 | 236 | 0.560 |
Why?
|
| Betacoronavirus | 2 | 2021 | 513 | 0.550 |
Why?
|
| Mice, Inbred NOD | 12 | 2024 | 897 | 0.550 |
Why?
|
| Cancer Vaccines | 4 | 2022 | 754 | 0.550 |
Why?
|
| Prognosis | 58 | 2024 | 22481 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2023 | 10385 | 0.550 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 2021 | 683 | 0.550 |
Why?
|
| Cytokines | 12 | 2023 | 2826 | 0.540 |
Why?
|
| Erythrocytes | 2 | 2016 | 337 | 0.540 |
Why?
|
| Leukemia, Myeloid | 7 | 2016 | 993 | 0.530 |
Why?
|
| Flow Cytometry | 15 | 2019 | 3045 | 0.520 |
Why?
|
| Cost of Illness | 1 | 2019 | 504 | 0.520 |
Why?
|
| Lymphocyte Depletion | 6 | 2024 | 316 | 0.520 |
Why?
|
| Leukapheresis | 12 | 2022 | 166 | 0.520 |
Why?
|
| Immunologic Factors | 3 | 2021 | 672 | 0.510 |
Why?
|
| Interleukin-15 | 6 | 2024 | 190 | 0.510 |
Why?
|
| Histocompatibility | 8 | 2022 | 183 | 0.500 |
Why?
|
| Pyrazines | 2 | 2024 | 510 | 0.500 |
Why?
|
| Tumor Virus Infections | 5 | 2020 | 248 | 0.500 |
Why?
|
| Antigens, Neoplasm | 10 | 2022 | 1580 | 0.490 |
Why?
|
| Glioblastoma | 6 | 2024 | 1776 | 0.490 |
Why?
|
| Acute Disease | 18 | 2024 | 2496 | 0.490 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 517 | 0.480 |
Why?
|
| Child | 52 | 2024 | 30546 | 0.480 |
Why?
|
| Transplant Recipients | 7 | 2021 | 336 | 0.480 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1301 | 0.470 |
Why?
|
| Stem Cell Factor | 7 | 2000 | 84 | 0.470 |
Why?
|
| Cell Engineering | 2 | 2021 | 35 | 0.460 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.450 |
Why?
|
| Megakaryocytes | 3 | 2022 | 129 | 0.440 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 7383 | 0.440 |
Why?
|
| Cell Differentiation | 11 | 2018 | 4117 | 0.440 |
Why?
|
| K562 Cells | 11 | 2021 | 345 | 0.430 |
Why?
|
| Clinical Trials as Topic | 23 | 2020 | 3845 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 29 | 2020 | 5071 | 0.420 |
Why?
|
| Tissue Engineering | 1 | 2015 | 255 | 0.420 |
Why?
|
| Cell Line, Tumor | 26 | 2024 | 14838 | 0.420 |
Why?
|
| Carmustine | 25 | 2018 | 224 | 0.420 |
Why?
|
| Blood Banks | 5 | 2021 | 28 | 0.420 |
Why?
|
| Prospective Studies | 35 | 2024 | 13417 | 0.410 |
Why?
|
| Transposases | 4 | 2016 | 69 | 0.410 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 90 | 0.400 |
Why?
|
| Receptors, KIR | 4 | 2022 | 64 | 0.400 |
Why?
|
| B-Lymphocytes, Regulatory | 3 | 2017 | 23 | 0.400 |
Why?
|
| Transplants | 1 | 2012 | 50 | 0.400 |
Why?
|
| Age Factors | 12 | 2024 | 5465 | 0.390 |
Why?
|
| Mycophenolic Acid | 5 | 2024 | 153 | 0.390 |
Why?
|
| Chromosome Aberrations | 8 | 2024 | 2031 | 0.390 |
Why?
|
| Fucosyltransferases | 4 | 2016 | 78 | 0.390 |
Why?
|
| CD40 Antigens | 2 | 2012 | 106 | 0.390 |
Why?
|
| Severity of Illness Index | 8 | 2023 | 4375 | 0.380 |
Why?
|
| Deoxycytidine | 8 | 2024 | 1389 | 0.370 |
Why?
|
| Adenine Nucleotides | 5 | 2016 | 365 | 0.370 |
Why?
|
| Mortality | 3 | 2018 | 347 | 0.370 |
Why?
|
| Ethylenediamines | 2 | 2008 | 22 | 0.360 |
Why?
|
| Cryopreservation | 6 | 2021 | 151 | 0.360 |
Why?
|
| Immunologic Memory | 5 | 2016 | 380 | 0.360 |
Why?
|
| Mice, SCID | 14 | 2018 | 1825 | 0.360 |
Why?
|
| Interferon-gamma | 10 | 2019 | 1180 | 0.360 |
Why?
|
| B-Lymphocytes | 6 | 2022 | 1424 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 1401 | 0.350 |
Why?
|
| Amifostine | 3 | 1996 | 99 | 0.350 |
Why?
|
| Interleukins | 3 | 2024 | 341 | 0.350 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 125 | 0.350 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2024 | 838 | 0.350 |
Why?
|
| Arabinonucleosides | 5 | 2016 | 470 | 0.340 |
Why?
|
| Herpesvirus 4, Human | 7 | 2023 | 960 | 0.340 |
Why?
|
| Risk Factors | 36 | 2024 | 17900 | 0.340 |
Why?
|
| Chelating Agents | 2 | 2008 | 130 | 0.340 |
Why?
|
| Feasibility Studies | 13 | 2023 | 2363 | 0.340 |
Why?
|
| Signal Transduction | 15 | 2024 | 12102 | 0.340 |
Why?
|
| Graft Rejection | 7 | 2018 | 847 | 0.340 |
Why?
|
| Herpesviridae Infections | 2 | 2016 | 181 | 0.340 |
Why?
|
| Immune System | 2 | 2010 | 275 | 0.340 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 1013 | 0.330 |
Why?
|
| Boronic Acids | 1 | 2011 | 354 | 0.330 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2018 | 604 | 0.330 |
Why?
|
| Induction Chemotherapy | 4 | 2023 | 670 | 0.330 |
Why?
|
| Antiviral Agents | 8 | 2023 | 1253 | 0.330 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 878 | 0.320 |
Why?
|
| Cytarabine | 8 | 2024 | 2013 | 0.320 |
Why?
|
| Blood Component Removal | 6 | 2015 | 119 | 0.320 |
Why?
|
| Skin Neoplasms | 7 | 2021 | 4892 | 0.320 |
Why?
|
| Child, Preschool | 24 | 2023 | 17048 | 0.320 |
Why?
|
| Regeneration | 2 | 2010 | 283 | 0.310 |
Why?
|
| Congresses as Topic | 1 | 2010 | 298 | 0.310 |
Why?
|
| HLA-A2 Antigen | 3 | 2024 | 172 | 0.310 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2021 | 625 | 0.310 |
Why?
|
| CD28 Antigens | 3 | 2024 | 203 | 0.310 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2009 | 189 | 0.310 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 3 | 2013 | 46 | 0.310 |
Why?
|
| Herpesvirus 1, Human | 4 | 2016 | 115 | 0.300 |
Why?
|
| Photopheresis | 3 | 2021 | 79 | 0.300 |
Why?
|
| Viral Matrix Proteins | 3 | 2020 | 181 | 0.300 |
Why?
|
| Pyrimidines | 9 | 2017 | 3667 | 0.300 |
Why?
|
| Follow-Up Studies | 29 | 2021 | 15212 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 565 | 0.300 |
Why?
|
| Transplantation Chimera | 6 | 2015 | 173 | 0.290 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2019 | 33 | 0.290 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2009 | 247 | 0.290 |
Why?
|
| Pyrazoles | 4 | 2024 | 1544 | 0.290 |
Why?
|
| Myeloblastin | 3 | 2016 | 65 | 0.290 |
Why?
|
| Dexamethasone | 6 | 2023 | 1507 | 0.290 |
Why?
|
| Positron-Emission Tomography | 8 | 2022 | 2196 | 0.290 |
Why?
|
| Receptors, Antigen | 3 | 2013 | 68 | 0.290 |
Why?
|
| Bacteroides | 2 | 2024 | 54 | 0.280 |
Why?
|
| Neoplasm Proteins | 5 | 2021 | 3346 | 0.280 |
Why?
|
| Haplotypes | 8 | 2024 | 909 | 0.280 |
Why?
|
| Copper | 1 | 2008 | 165 | 0.280 |
Why?
|
| Time Factors | 25 | 2021 | 13021 | 0.280 |
Why?
|
| E-Selectin | 3 | 2016 | 106 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2024 | 4961 | 0.280 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 2 | 2018 | 22 | 0.270 |
Why?
|
| Philadelphia Chromosome | 3 | 2024 | 852 | 0.270 |
Why?
|
| Donor Selection | 3 | 2022 | 110 | 0.270 |
Why?
|
| Sulfonamides | 4 | 2024 | 1933 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2024 | 1347 | 0.270 |
Why?
|
| Cause of Death | 4 | 2024 | 788 | 0.270 |
Why?
|
| Tumor Microenvironment | 11 | 2022 | 3031 | 0.270 |
Why?
|
| Living Donors | 4 | 2010 | 175 | 0.270 |
Why?
|
| Cell Polarity | 1 | 2007 | 212 | 0.270 |
Why?
|
| Adenoviridae | 7 | 2013 | 1497 | 0.270 |
Why?
|
| Membrane Glycoproteins | 6 | 2014 | 1095 | 0.270 |
Why?
|
| Therapeutics | 1 | 2006 | 31 | 0.270 |
Why?
|
| Leukocyte Count | 8 | 2010 | 735 | 0.270 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 31008 | 0.270 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 864 | 0.260 |
Why?
|
| Gene Expression Regulation, Leukemic | 5 | 2016 | 586 | 0.260 |
Why?
|
| Lymphocytes | 6 | 2024 | 1275 | 0.260 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2023 | 104 | 0.260 |
Why?
|
| Cladribine | 2 | 2024 | 253 | 0.260 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2011 | 593 | 0.260 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 480 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 3 | 2024 | 1109 | 0.260 |
Why?
|
| Cystitis | 2 | 2021 | 109 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 128 | 0.250 |
Why?
|
| Chimerism | 2 | 2017 | 65 | 0.250 |
Why?
|
| Thymidine Kinase | 4 | 2016 | 223 | 0.250 |
Why?
|
| Quality Control | 2 | 2021 | 461 | 0.250 |
Why?
|
| Brain Neoplasms | 6 | 2024 | 4958 | 0.250 |
Why?
|
| Ovarian Neoplasms | 12 | 2004 | 4795 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 1585 | 0.250 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2024 | 513 | 0.250 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2017 | 162 | 0.250 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2022 | 228 | 0.250 |
Why?
|
| Alleles | 6 | 2017 | 2602 | 0.240 |
Why?
|
| Recombinant Proteins | 15 | 2009 | 3028 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2024 | 3919 | 0.240 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2024 | 15 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1387 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 213 | 0.240 |
Why?
|
| Immunocompromised Host | 6 | 2018 | 719 | 0.240 |
Why?
|
| Opportunistic Infections | 3 | 2015 | 234 | 0.240 |
Why?
|
| Sezary Syndrome | 2 | 2021 | 171 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2023 | 5403 | 0.240 |
Why?
|
| Pentostatin | 2 | 2017 | 121 | 0.240 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2024 | 63 | 0.240 |
Why?
|
| Growth Substances | 6 | 1999 | 326 | 0.240 |
Why?
|
| Cisplatin | 24 | 2023 | 2496 | 0.230 |
Why?
|
| Monocytes | 4 | 2017 | 790 | 0.230 |
Why?
|
| Epitopes | 4 | 2018 | 707 | 0.230 |
Why?
|
| Models, Biological | 4 | 2019 | 3194 | 0.230 |
Why?
|
| Adenoviridae Infections | 3 | 2013 | 114 | 0.230 |
Why?
|
| Receptors, CCR5 | 4 | 2012 | 55 | 0.230 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2006 | 637 | 0.230 |
Why?
|
| Comorbidity | 5 | 2023 | 2392 | 0.230 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2024 | 41 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Lymphocyte Count | 8 | 2016 | 485 | 0.220 |
Why?
|
| T-Cell Antigen Receptor Specificity | 3 | 2016 | 92 | 0.220 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 914 | 0.220 |
Why?
|
| Incidence | 11 | 2024 | 5828 | 0.220 |
Why?
|
| Medical Audit | 2 | 2019 | 195 | 0.220 |
Why?
|
| Epigenesis, Genetic | 2 | 2024 | 1442 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2009 | 2653 | 0.220 |
Why?
|
| Blood Cell Count | 4 | 2012 | 233 | 0.220 |
Why?
|
| Magnetics | 5 | 2011 | 98 | 0.220 |
Why?
|
| Azacitidine | 3 | 2024 | 1218 | 0.210 |
Why?
|
| Whole-Body Irradiation | 6 | 2017 | 323 | 0.210 |
Why?
|
| Stroke | 2 | 2024 | 1058 | 0.210 |
Why?
|
| Granulocytes | 4 | 2016 | 244 | 0.210 |
Why?
|
| Kidney Diseases | 3 | 2016 | 694 | 0.210 |
Why?
|
| Perforin | 2 | 2021 | 52 | 0.210 |
Why?
|
| Interleukin-2 | 4 | 2016 | 889 | 0.210 |
Why?
|
| Aniline Compounds | 1 | 2024 | 206 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 359 | 0.210 |
Why?
|
| Nitrogen Mustard Compounds | 2 | 2014 | 74 | 0.210 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 224 | 0.210 |
Why?
|
| Benzylamines | 4 | 2019 | 98 | 0.210 |
Why?
|
| Viremia | 1 | 2023 | 182 | 0.200 |
Why?
|
| Risk | 5 | 2017 | 1940 | 0.200 |
Why?
|
| Organophosphonates | 2 | 2016 | 63 | 0.200 |
Why?
|
| rho-Associated Kinases | 1 | 2022 | 80 | 0.200 |
Why?
|
| DNA Transposable Elements | 2 | 2016 | 250 | 0.200 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 4498 | 0.200 |
Why?
|
| Bayes Theorem | 5 | 2022 | 1060 | 0.200 |
Why?
|
| Interleukin-10 | 3 | 2016 | 484 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2024 | 7784 | 0.200 |
Why?
|
| Drug Administration Schedule | 16 | 2015 | 3532 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2016 | 1642 | 0.200 |
Why?
|
| Cytosine | 2 | 2016 | 155 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2024 | 235 | 0.190 |
Why?
|
| Stem Cells | 5 | 2024 | 1217 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 186 | 0.190 |
Why?
|
| Drug Therapy, Combination | 11 | 2022 | 2344 | 0.190 |
Why?
|
| RNA, Messenger | 4 | 2014 | 6398 | 0.190 |
Why?
|
| Immunophenotyping | 9 | 2019 | 1726 | 0.190 |
Why?
|
| Alkylating Agents | 5 | 2024 | 81 | 0.190 |
Why?
|
| Case-Control Studies | 11 | 2024 | 6237 | 0.190 |
Why?
|
| Translocation, Genetic | 5 | 2023 | 1285 | 0.190 |
Why?
|
| Idarubicin | 1 | 2023 | 459 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 12 | 2016 | 4480 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 134 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Brain Ischemia | 1 | 2024 | 311 | 0.190 |
Why?
|
| Integrin alpha4beta1 | 2 | 2014 | 46 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 62 | 0.190 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2020 | 32 | 0.190 |
Why?
|
| Patient Selection | 5 | 2017 | 2026 | 0.180 |
Why?
|
| Quality of Life | 4 | 2023 | 4775 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2017 | 1097 | 0.180 |
Why?
|
| HIV-1 | 4 | 2018 | 639 | 0.180 |
Why?
|
| Filgrastim | 9 | 2009 | 194 | 0.180 |
Why?
|
| HLA-DRB1 Chains | 2 | 2018 | 89 | 0.180 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2014 | 124 | 0.180 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 101 | 0.180 |
Why?
|
| Blood Component Transfusion | 2 | 2017 | 87 | 0.180 |
Why?
|
| Antibodies, Bispecific | 2 | 2022 | 282 | 0.180 |
Why?
|
| Cross Reactions | 1 | 2021 | 263 | 0.180 |
Why?
|
| Immunization, Passive | 1 | 2021 | 188 | 0.180 |
Why?
|
| Accreditation | 2 | 2000 | 137 | 0.180 |
Why?
|
| Cohort Studies | 12 | 2022 | 9474 | 0.180 |
Why?
|
| Inpatients | 2 | 2017 | 686 | 0.180 |
Why?
|
| Neoplasm Staging | 13 | 2024 | 14012 | 0.180 |
Why?
|
| Pancytopenia | 3 | 2016 | 119 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2023 | 2308 | 0.180 |
Why?
|
| Rituximab | 5 | 2023 | 1593 | 0.180 |
Why?
|
| Lymphocyte Subsets | 3 | 2012 | 138 | 0.180 |
Why?
|
| Cell Survival | 5 | 2016 | 3063 | 0.180 |
Why?
|
| Vaccination | 2 | 2022 | 1164 | 0.180 |
Why?
|
| CRISPR-Cas Systems | 2 | 2021 | 362 | 0.180 |
Why?
|
| Genotype | 4 | 2016 | 4255 | 0.170 |
Why?
|
| Colony-Stimulating Factors | 4 | 1994 | 83 | 0.170 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 607 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 4 | 2021 | 1457 | 0.170 |
Why?
|
| Integrins | 1 | 2021 | 275 | 0.170 |
Why?
|
| Sirolimus | 2 | 2022 | 831 | 0.170 |
Why?
|
| Neutropenia | 3 | 2022 | 1006 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 396 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 169 | 0.170 |
Why?
|
| Proportional Hazards Models | 10 | 2024 | 5102 | 0.170 |
Why?
|
| Bortezomib | 3 | 2022 | 543 | 0.170 |
Why?
|
| Blood Cells | 3 | 2010 | 129 | 0.170 |
Why?
|
| Autografts | 4 | 2023 | 179 | 0.170 |
Why?
|
| Biomarkers | 6 | 2019 | 5060 | 0.170 |
Why?
|
| Blood Safety | 1 | 2019 | 11 | 0.170 |
Why?
|
| Herpesvirus 6, Human | 2 | 2014 | 81 | 0.170 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 88 | 0.170 |
Why?
|
| Core Binding Factors | 1 | 2020 | 112 | 0.170 |
Why?
|
| Transplantation, Heterologous | 7 | 2018 | 1054 | 0.170 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 184 | 0.160 |
Why?
|
| Methotrexate | 8 | 2023 | 1025 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2020 | 294 | 0.160 |
Why?
|
| Infant | 12 | 2019 | 13989 | 0.160 |
Why?
|
| Steroids | 5 | 2021 | 372 | 0.160 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 20 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 344 | 0.160 |
Why?
|
| Arabinofuranosyluracil | 4 | 2016 | 46 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 402 | 0.160 |
Why?
|
| CD4 Antigens | 4 | 2016 | 170 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2023 | 1564 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 183 | 0.160 |
Why?
|
| Risk Assessment | 9 | 2024 | 6768 | 0.160 |
Why?
|
| Antigens, Viral | 3 | 2019 | 520 | 0.160 |
Why?
|
| Antibodies | 3 | 2016 | 809 | 0.160 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2018 | 45 | 0.160 |
Why?
|
| Lung Transplantation | 1 | 2023 | 383 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 327 | 0.160 |
Why?
|
| Primary Cell Culture | 2 | 2016 | 200 | 0.160 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2018 | 10 | 0.160 |
Why?
|
| Multivariate Analysis | 12 | 2017 | 4328 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 12 | 2018 | 5759 | 0.160 |
Why?
|
| Ehrlichiosis | 1 | 2018 | 18 | 0.150 |
Why?
|
| Immunity, Cellular | 3 | 2019 | 440 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 364 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 342 | 0.150 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 416 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 498 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 239 | 0.150 |
Why?
|
| Piperazines | 5 | 2012 | 2145 | 0.150 |
Why?
|
| Everolimus | 1 | 2020 | 436 | 0.150 |
Why?
|
| Culture Media | 4 | 2009 | 343 | 0.150 |
Why?
|
| Blood Preservation | 2 | 2014 | 60 | 0.150 |
Why?
|
| Oligosaccharides | 2 | 2016 | 113 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 92 | 0.150 |
Why?
|
| Ependymoma | 1 | 2020 | 265 | 0.150 |
Why?
|
| Psychometrics | 1 | 2023 | 971 | 0.150 |
Why?
|
| Viral Load | 5 | 2019 | 485 | 0.150 |
Why?
|
| Blood Transfusion | 2 | 2018 | 581 | 0.150 |
Why?
|
| Cognition Disorders | 1 | 2023 | 762 | 0.150 |
Why?
|
| Thiotepa | 8 | 2012 | 132 | 0.150 |
Why?
|
| Melanoma | 9 | 2021 | 5595 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2024 | 216 | 0.150 |
Why?
|
| Pancreatitis | 1 | 2000 | 295 | 0.150 |
Why?
|
| Lymphocyte Transfusion | 4 | 2017 | 174 | 0.150 |
Why?
|
| CD56 Antigen | 2 | 2016 | 85 | 0.140 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 11 | 0.140 |
Why?
|
| Single-Chain Antibodies | 2 | 2024 | 61 | 0.140 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 97 | 0.140 |
Why?
|
| Freezing | 1 | 2016 | 62 | 0.140 |
Why?
|
| Niacinamide | 1 | 2018 | 428 | 0.140 |
Why?
|
| Interleukin-12 | 2 | 2009 | 267 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2018 | 131 | 0.140 |
Why?
|
| Interleukin-6 | 4 | 2008 | 1051 | 0.140 |
Why?
|
| Immunity | 1 | 2019 | 355 | 0.140 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2018 | 120 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 376 | 0.140 |
Why?
|
| Natural Killer T-Cells | 1 | 2018 | 121 | 0.140 |
Why?
|
| Genetic Therapy | 5 | 2018 | 1714 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 728 | 0.140 |
Why?
|
| Body Fluids | 1 | 2017 | 121 | 0.140 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 88 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2005 | 690 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2005 | 500 | 0.140 |
Why?
|
| Lung | 4 | 2023 | 3300 | 0.130 |
Why?
|
| Urologic Diseases | 1 | 2016 | 83 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 70 | 0.130 |
Why?
|
| CD40 Ligand | 2 | 2007 | 130 | 0.130 |
Why?
|
| Immunologic Surveillance | 2 | 2018 | 59 | 0.130 |
Why?
|
| Gastrointestinal Tract | 2 | 2017 | 324 | 0.130 |
Why?
|
| Immunoglobulin M | 2 | 2014 | 359 | 0.130 |
Why?
|
| Deoxyribonucleases | 1 | 2016 | 55 | 0.130 |
Why?
|
| Mucor | 1 | 2015 | 18 | 0.130 |
Why?
|
| Tissue Banks | 2 | 1997 | 51 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 1199 | 0.130 |
Why?
|
| Hydroxamic Acids | 2 | 2016 | 454 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 551 | 0.130 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2016 | 50 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1032 | 0.130 |
Why?
|
| Genome, Fungal | 1 | 2015 | 56 | 0.130 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 43 | 0.130 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 105 | 0.130 |
Why?
|
| Edema | 1 | 2017 | 263 | 0.130 |
Why?
|
| Disease Progression | 8 | 2024 | 6855 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 139 | 0.130 |
Why?
|
| Consolidation Chemotherapy | 1 | 2016 | 153 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 125 | 0.130 |
Why?
|
| Smad Proteins | 1 | 2015 | 82 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2015 | 76 | 0.130 |
Why?
|
| Cell Division | 8 | 2000 | 2657 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2018 | 503 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 225 | 0.130 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2016 | 254 | 0.130 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 478 | 0.120 |
Why?
|
| Infusions, Intravenous | 8 | 2012 | 1437 | 0.120 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2014 | 10 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1996 | 128 | 0.120 |
Why?
|
| Radioimmunotherapy | 1 | 1995 | 128 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 1301 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2020 | 572 | 0.120 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2016 | 89 | 0.120 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.120 |
Why?
|
| Proteomics | 2 | 2019 | 1427 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 267 | 0.120 |
Why?
|
| Chemokine CXCL12 | 2 | 2013 | 131 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2007 | 425 | 0.120 |
Why?
|
| Secretory Vesicles | 1 | 2014 | 41 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2017 | 1838 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 352 | 0.120 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 12028 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 6193 | 0.120 |
Why?
|
| Probability | 3 | 2012 | 886 | 0.120 |
Why?
|
| Treatment Failure | 6 | 2017 | 1428 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 463 | 0.120 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 51 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 760 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2015 | 118 | 0.120 |
Why?
|
| Genetic Vectors | 6 | 2020 | 1857 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 472 | 0.120 |
Why?
|
| Antigen Presentation | 3 | 2013 | 286 | 0.120 |
Why?
|
| Syndrome | 1 | 2017 | 1407 | 0.120 |
Why?
|
| Yttrium Radioisotopes | 1 | 1995 | 210 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 15 | 0.110 |
Why?
|
| Blood Donors | 2 | 2009 | 173 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2017 | 412 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 3181 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 173 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 1902 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 882 | 0.110 |
Why?
|
| Lymphatic Metastasis | 8 | 2009 | 4963 | 0.110 |
Why?
|
| Roseolovirus Infections | 1 | 2014 | 39 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1062 | 0.110 |
Why?
|
| Antifungal Agents | 3 | 2015 | 879 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 6255 | 0.110 |
Why?
|
| Disease Management | 1 | 2019 | 1089 | 0.110 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2013 | 25 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 2 | 2017 | 763 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 473 | 0.110 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2013 | 43 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 127 | 0.110 |
Why?
|
| Retroviridae | 3 | 2020 | 373 | 0.110 |
Why?
|
| Doxorubicin | 10 | 2009 | 3145 | 0.110 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2013 | 67 | 0.110 |
Why?
|
| Registries | 3 | 2012 | 2209 | 0.110 |
Why?
|
| Europe | 3 | 2015 | 658 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 5 | 2009 | 2651 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2014 | 419 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2011 | 1180 | 0.100 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 10706 | 0.100 |
Why?
|
| Mice, Knockout | 4 | 2021 | 5731 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Heterografts | 3 | 2021 | 739 | 0.100 |
Why?
|
| Mucus | 2 | 2022 | 109 | 0.100 |
Why?
|
| United States | 9 | 2019 | 15855 | 0.100 |
Why?
|
| Lower Gastrointestinal Tract | 2 | 2023 | 29 | 0.100 |
Why?
|
| Acetates | 2 | 2024 | 122 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2024 | 175 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 618 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 304 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 544 | 0.100 |
Why?
|
| Culture Techniques | 2 | 2009 | 146 | 0.100 |
Why?
|
| Transfection | 3 | 2008 | 3118 | 0.100 |
Why?
|
| Immunomagnetic Separation | 3 | 1997 | 35 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2014 | 1028 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 2196 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 366 | 0.100 |
Why?
|
| Germinoma | 2 | 2004 | 82 | 0.100 |
Why?
|
| Propensity Score | 3 | 2022 | 771 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2023 | 3656 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2018 | 2422 | 0.100 |
Why?
|
| Chronic Disease | 5 | 2022 | 1828 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2013 | 287 | 0.100 |
Why?
|
| Life Tables | 3 | 2000 | 120 | 0.100 |
Why?
|
| Imatinib Mesylate | 4 | 2012 | 1691 | 0.100 |
Why?
|
| Immunosorbent Techniques | 3 | 1996 | 55 | 0.100 |
Why?
|
| Microbiota | 1 | 2018 | 547 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 558 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 1710 | 0.100 |
Why?
|
| Critical Illness | 1 | 2017 | 740 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 413 | 0.100 |
Why?
|
| Adipocytes | 1 | 2013 | 298 | 0.100 |
Why?
|
| Cytogenetic Analysis | 3 | 2020 | 574 | 0.090 |
Why?
|
| Mucins | 2 | 2022 | 289 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 2573 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 659 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 6 | 1997 | 253 | 0.090 |
Why?
|
| Retreatment | 3 | 2018 | 447 | 0.090 |
Why?
|
| Anemia, Aplastic | 2 | 2010 | 232 | 0.090 |
Why?
|
| Sample Size | 1 | 2012 | 213 | 0.090 |
Why?
|
| Gene Expression | 6 | 2016 | 3642 | 0.090 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2010 | 24 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 1267 | 0.090 |
Why?
|
| Bone Marrow Diseases | 3 | 2000 | 186 | 0.090 |
Why?
|
| Peptides | 4 | 2019 | 1504 | 0.090 |
Why?
|
| Cell Line | 7 | 2016 | 5339 | 0.090 |
Why?
|
| Etoposide | 4 | 2018 | 907 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 1136 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2016 | 1473 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2016 | 423 | 0.090 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2011 | 58 | 0.090 |
Why?
|
| Thrombopoietin | 3 | 2000 | 102 | 0.090 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2012 | 264 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 59 | 0.090 |
Why?
|
| Stromal Cells | 3 | 2014 | 826 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2009 | 368 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 1998 | 794 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 549 | 0.090 |
Why?
|
| Benzamides | 4 | 2012 | 1879 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2394 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1089 | 0.090 |
Why?
|
| Mitoxantrone | 2 | 2004 | 227 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2023 | 2073 | 0.090 |
Why?
|
| Mutation | 7 | 2024 | 15911 | 0.090 |
Why?
|
| CD8 Antigens | 2 | 2013 | 174 | 0.090 |
Why?
|
| Leukocyte Common Antigens | 3 | 2023 | 191 | 0.090 |
Why?
|
| Leukocytes | 1 | 2012 | 422 | 0.090 |
Why?
|
| Plastics | 1 | 2011 | 97 | 0.090 |
Why?
|
| Carboplatin | 7 | 2022 | 880 | 0.090 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 135 | 0.090 |
Why?
|
| Glioma | 1 | 2021 | 1978 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2017 | 3478 | 0.090 |
Why?
|
| Immunohistochemistry | 11 | 2011 | 7665 | 0.090 |
Why?
|
| Adenosine | 1 | 2012 | 296 | 0.090 |
Why?
|
| Transduction, Genetic | 3 | 2021 | 494 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1994 | 517 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 381 | 0.090 |
Why?
|
| Prodrugs | 1 | 2011 | 226 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2014 | 2886 | 0.080 |
Why?
|
| Ureteral Obstruction | 1 | 2011 | 146 | 0.080 |
Why?
|
| Genes, MHC Class I | 1 | 2009 | 50 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2016 | 763 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2011 | 384 | 0.080 |
Why?
|
| Oligopeptides | 2 | 2022 | 447 | 0.080 |
Why?
|
| Sequence Deletion | 1 | 2012 | 909 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 153 | 0.080 |
Why?
|
| Glycoproteins | 3 | 2014 | 779 | 0.080 |
Why?
|
| DNA Methylation | 3 | 2018 | 2767 | 0.080 |
Why?
|
| HIV Infections | 4 | 2012 | 2155 | 0.080 |
Why?
|
| Fluorouracil | 6 | 2009 | 1989 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2012 | 1144 | 0.080 |
Why?
|
| Hematology | 3 | 2017 | 99 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 2008 | 247 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2222 | 0.080 |
Why?
|
| Central Nervous System | 2 | 2022 | 453 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 114 | 0.080 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2009 | 30 | 0.080 |
Why?
|
| Immune Tolerance | 3 | 2017 | 427 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2013 | 903 | 0.080 |
Why?
|
| AC133 Antigen | 2 | 2006 | 107 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2009 | 198 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 622 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2018 | 4943 | 0.080 |
Why?
|
| Myocardium | 2 | 2011 | 1233 | 0.080 |
Why?
|
| Teaching | 1 | 2010 | 251 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2014 | 3588 | 0.080 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2009 | 58 | 0.080 |
Why?
|
| In Vitro Techniques | 6 | 2010 | 1710 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 738 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2009 | 179 | 0.080 |
Why?
|
| Thymus Gland | 2 | 2007 | 311 | 0.080 |
Why?
|
| Receptors, Natural Killer Cell | 2 | 2021 | 16 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 723 | 0.080 |
Why?
|
| Medical Oncology | 4 | 2018 | 1465 | 0.080 |
Why?
|
| Langerhans Cells | 1 | 2008 | 53 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2009 | 286 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 273 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2014 | 756 | 0.080 |
Why?
|
| Peptide Fragments | 4 | 2016 | 1309 | 0.080 |
Why?
|
| Transplantation Immunology | 2 | 2019 | 107 | 0.070 |
Why?
|
| Quinazolines | 2 | 2024 | 956 | 0.070 |
Why?
|
| Ferritins | 2 | 2021 | 155 | 0.070 |
Why?
|
| Stomatitis, Herpetic | 1 | 2007 | 6 | 0.070 |
Why?
|
| Drug Interactions | 3 | 2018 | 574 | 0.070 |
Why?
|
| Neoplasm Metastasis | 8 | 2004 | 5310 | 0.070 |
Why?
|
| Glycosylation | 2 | 2019 | 230 | 0.070 |
Why?
|
| Feces | 2 | 2024 | 861 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 4963 | 0.070 |
Why?
|
| Rabbits | 2 | 2024 | 1028 | 0.070 |
Why?
|
| Infant, Newborn | 6 | 2016 | 8699 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2010 | 275 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2014 | 1564 | 0.070 |
Why?
|
| Forecasting | 2 | 2000 | 702 | 0.070 |
Why?
|
| Plasmids | 3 | 2016 | 936 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2008 | 219 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2007 | 53 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2007 | 233 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2023 | 2376 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 1469 | 0.070 |
Why?
|
| Leukocyte Transfusion | 1 | 2006 | 44 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 295 | 0.070 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1991 | 230 | 0.070 |
Why?
|
| Premedication | 2 | 2016 | 133 | 0.070 |
Why?
|
| Peptides, Cyclic | 1 | 2007 | 139 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 100 | 0.070 |
Why?
|
| Transgenes | 3 | 2016 | 576 | 0.070 |
Why?
|
| Lung Diseases | 4 | 2016 | 755 | 0.070 |
Why?
|
| Area Under Curve | 4 | 2017 | 729 | 0.060 |
Why?
|
| Monosomy | 2 | 2017 | 98 | 0.060 |
Why?
|
| Phagocytosis | 2 | 2006 | 292 | 0.060 |
Why?
|
| Metagenome | 2 | 2017 | 193 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 113 | 0.060 |
Why?
|
| Epitope Mapping | 2 | 2018 | 110 | 0.060 |
Why?
|
| Drug Evaluation | 6 | 1991 | 432 | 0.060 |
Why?
|
| Osteonecrosis | 1 | 1986 | 56 | 0.060 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2022 | 460 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2005 | 4001 | 0.060 |
Why?
|
| Herpesvirus 7, Human | 1 | 2005 | 4 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2012 | 172 | 0.060 |
Why?
|
| Interleukin-3 | 2 | 1997 | 106 | 0.060 |
Why?
|
| Femur | 1 | 1986 | 161 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2006 | 219 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 170 | 0.060 |
Why?
|
| Paclitaxel | 5 | 1999 | 2101 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 17 | 0.060 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2024 | 37 | 0.060 |
Why?
|
| Gene Transfer Techniques | 3 | 2016 | 804 | 0.060 |
Why?
|
| Respiratory Function Tests | 2 | 2024 | 354 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2005 | 137 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2018 | 823 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2024 | 89 | 0.060 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2017 | 347 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 475 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2017 | 510 | 0.060 |
Why?
|
| Glycolysis | 2 | 2021 | 530 | 0.060 |
Why?
|
| Graft vs Tumor Effect | 1 | 2004 | 143 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2005 | 107 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1311 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5569 | 0.060 |
Why?
|
| Apoptosis | 5 | 2023 | 7754 | 0.060 |
Why?
|
| Texas | 3 | 2013 | 6447 | 0.060 |
Why?
|
| Mothers | 2 | 2022 | 416 | 0.060 |
Why?
|
| Smad3 Protein | 1 | 2024 | 123 | 0.060 |
Why?
|
| Influenza Vaccines | 3 | 2016 | 496 | 0.060 |
Why?
|
| Calcineurin Inhibitors | 1 | 2024 | 67 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2022 | 3408 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 488 | 0.060 |
Why?
|
| Heart | 1 | 2010 | 1195 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2005 | 99 | 0.060 |
Why?
|
| Cell Line, Transformed | 3 | 2014 | 427 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 669 | 0.060 |
Why?
|
| Cytogenetics | 2 | 2014 | 152 | 0.060 |
Why?
|
| Complement Inactivating Agents | 1 | 2023 | 17 | 0.060 |
Why?
|
| Interleukin-7 | 1 | 2023 | 92 | 0.050 |
Why?
|
| Complement C5a | 1 | 2023 | 35 | 0.050 |
Why?
|
| Microspheres | 3 | 1994 | 238 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2024 | 152 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2024 | 314 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 1335 | 0.050 |
Why?
|
| Phosphatidylinositols | 1 | 2023 | 69 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2023 | 390 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 238 | 0.050 |
Why?
|
| Cell Lineage | 4 | 2012 | 701 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.050 |
Why?
|
| Thiazoles | 1 | 2007 | 723 | 0.050 |
Why?
|
| Burkitt Lymphoma | 2 | 2021 | 348 | 0.050 |
Why?
|
| Adenine | 2 | 2017 | 672 | 0.050 |
Why?
|
| Xylose | 1 | 2022 | 18 | 0.050 |
Why?
|
| Genes, Reporter | 4 | 2011 | 820 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2014 | 1140 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 75 | 0.050 |
Why?
|
| Prednisone | 1 | 1986 | 1033 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2474 | 0.050 |
Why?
|
| Pandemics | 2 | 2024 | 1610 | 0.050 |
Why?
|
| Anemia, Sideroblastic | 1 | 2003 | 57 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 201 | 0.050 |
Why?
|
| Brain | 3 | 2023 | 4213 | 0.050 |
Why?
|
| Linear Models | 1 | 2006 | 1097 | 0.050 |
Why?
|
| Chromosome Inversion | 1 | 2023 | 197 | 0.050 |
Why?
|
| Polyamines | 1 | 2022 | 80 | 0.050 |
Why?
|
| Endothelium | 1 | 2003 | 156 | 0.050 |
Why?
|
| Cross Infection | 1 | 2007 | 549 | 0.050 |
Why?
|
| Mycoses | 1 | 2006 | 393 | 0.050 |
Why?
|
| Biopsy | 3 | 2020 | 3483 | 0.050 |
Why?
|
| HLA-DP beta-Chains | 1 | 2022 | 16 | 0.050 |
Why?
|
| Family | 2 | 2021 | 784 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 63 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2018 | 1320 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 3 | 1999 | 232 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2023 | 196 | 0.050 |
Why?
|
| Hemocyanins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2009 | 2320 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 885 | 0.050 |
Why?
|
| Immunological Synapses | 2 | 2012 | 31 | 0.050 |
Why?
|
| Sepsis | 1 | 2007 | 686 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2008 | 613 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 212 | 0.050 |
Why?
|
| Granzymes | 2 | 2014 | 94 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 703 | 0.050 |
Why?
|
| Age Distribution | 2 | 2017 | 727 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| Immunity, Innate | 2 | 2021 | 700 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 195 | 0.050 |
Why?
|
| Aerobiosis | 1 | 2021 | 31 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 113 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5149 | 0.050 |
Why?
|
| Bacteremia | 1 | 2007 | 720 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2006 | 654 | 0.050 |
Why?
|
| Electroporation | 2 | 2013 | 127 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1579 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2012 | 353 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2021 | 116 | 0.050 |
Why?
|
| Infusions, Intraventricular | 1 | 2020 | 28 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2022 | 247 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1077 | 0.050 |
Why?
|
| Piperidines | 2 | 2017 | 1098 | 0.050 |
Why?
|
| Blood | 1 | 2021 | 170 | 0.050 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 152 | 0.050 |
Why?
|
| Haploidy | 2 | 2010 | 43 | 0.040 |
Why?
|
| Liver Diseases | 3 | 2017 | 602 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2020 | 104 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5255 | 0.040 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2020 | 37 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 7103 | 0.040 |
Why?
|
| Spleen | 2 | 2013 | 726 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 1585 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 167 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 4223 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 179 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 1129 | 0.040 |
Why?
|
| Philadelphia | 1 | 2000 | 36 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 269 | 0.040 |
Why?
|
| Ki-1 Antigen | 1 | 2021 | 186 | 0.040 |
Why?
|
| France | 1 | 2000 | 122 | 0.040 |
Why?
|
| Gestational Age | 2 | 2021 | 1174 | 0.040 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 50 | 0.040 |
Why?
|
| Oophoritis | 1 | 1999 | 3 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 122 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 274 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 2455 | 0.040 |
Why?
|
| Leukopenia | 3 | 2007 | 152 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Optic Disk | 1 | 1999 | 54 | 0.040 |
Why?
|
| Luciferases, Firefly | 2 | 2009 | 40 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2020 | 208 | 0.040 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2019 | 16 | 0.040 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 5923 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 1999 | 82 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 213 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 1160 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2014 | 149 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 9041 | 0.040 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 199 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 324 | 0.040 |
Why?
|
| JC Virus | 1 | 2018 | 48 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 361 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 853 | 0.040 |
Why?
|
| Multiple Organ Failure | 1 | 2000 | 177 | 0.040 |
Why?
|
| Papilledema | 1 | 1999 | 87 | 0.040 |
Why?
|
| Professional Competence | 1 | 2000 | 135 | 0.040 |
Why?
|
| Luciferases | 2 | 2016 | 460 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2018 | 197 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2018 | 31 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 160 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2020 | 214 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1313 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 7895 | 0.040 |
Why?
|
| Hepatic Encephalopathy | 1 | 1999 | 90 | 0.040 |
Why?
|
| Fetus | 1 | 2002 | 674 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2018 | 55 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 788 | 0.040 |
Why?
|
| Diphtheria Toxin | 1 | 1998 | 83 | 0.040 |
Why?
|
| alpha-Thalassemia | 1 | 1998 | 11 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2018 | 170 | 0.040 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1997 | 39 | 0.040 |
Why?
|
| Antiemetics | 1 | 1999 | 122 | 0.040 |
Why?
|
| Radionuclide Imaging | 3 | 2012 | 655 | 0.040 |
Why?
|
| Kanamycin Kinase | 1 | 1997 | 22 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 2588 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 1554 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 657 | 0.040 |
Why?
|
| CD24 Antigen | 2 | 2014 | 88 | 0.040 |
Why?
|
| Liver | 2 | 2024 | 3089 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 1126 | 0.040 |
Why?
|
| Gene Editing | 1 | 2020 | 229 | 0.040 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 1998 | 37 | 0.040 |
Why?
|
| Galectins | 1 | 2018 | 73 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 1997 | 68 | 0.040 |
Why?
|
| Beijing | 1 | 2017 | 13 | 0.040 |
Why?
|
| Karyotype | 1 | 2018 | 237 | 0.040 |
Why?
|
| Chimera | 1 | 1998 | 152 | 0.040 |
Why?
|
| Drug Approval | 1 | 2018 | 174 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 160 | 0.040 |
Why?
|
| RNA Editing | 1 | 2018 | 97 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 1341 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2018 | 196 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 592 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2018 | 205 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 1998 | 7915 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2017 | 88 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 1571 | 0.040 |
Why?
|
| CD5 Antigens | 1 | 2017 | 130 | 0.040 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2017 | 36 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 151 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2016 | 29 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1999 | 894 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 155 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1542 | 0.040 |
Why?
|
| Rhodamines | 1 | 2016 | 48 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2013 | 2091 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 591 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 3402 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2018 | 299 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2017 | 187 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2014 | 1038 | 0.030 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2017 | 168 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 62 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 272 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 1998 | 234 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 1260 | 0.030 |
Why?
|
| Algorithms | 2 | 2022 | 3900 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2016 | 136 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 1462 | 0.030 |
Why?
|
| Drug Synergism | 3 | 2010 | 1359 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 617 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2016 | 194 | 0.030 |
Why?
|
| Xenopus | 1 | 2016 | 237 | 0.030 |
Why?
|
| U937 Cells | 1 | 2016 | 178 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2016 | 24 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 52 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 775 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2016 | 59 | 0.030 |
Why?
|
| Liver Failure | 1 | 2017 | 141 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1995 | 49 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1997 | 324 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2012 | 2033 | 0.030 |
Why?
|
| Onychomycosis | 1 | 2015 | 18 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 497 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2015 | 33 | 0.030 |
Why?
|
| Saliva | 1 | 2017 | 238 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 94 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 232 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 164 | 0.030 |
Why?
|
| Health Policy | 1 | 2018 | 278 | 0.030 |
Why?
|
| Bone Neoplasms | 4 | 1992 | 2664 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 2016 | 100 | 0.030 |
Why?
|
| China | 1 | 2017 | 635 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2016 | 314 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 749 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 411 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2016 | 203 | 0.030 |
Why?
|
| Facility Regulation and Control | 1 | 1995 | 2 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 252 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1997 | 452 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 121 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 627 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2006 | 342 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 374 | 0.030 |
Why?
|
| Fungemia | 1 | 2015 | 119 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1279 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 222 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1995 | 152 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2121 | 0.030 |
Why?
|
| Interferons | 1 | 2016 | 299 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2014 | 30 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 1998 | 5171 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1480 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2014 | 53 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2000 | 552 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2015 | 271 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 796 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 56 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2014 | 97 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2010 | 5676 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2014 | 84 | 0.030 |
Why?
|
| Ifosfamide | 2 | 2009 | 358 | 0.030 |
Why?
|
| Methylcellulose | 1 | 1994 | 10 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 2453 | 0.030 |
Why?
|
| Foscarnet | 1 | 2014 | 19 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 353 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 334 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 2013 | 14 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 540 | 0.030 |
Why?
|
| Laboratories | 1 | 1995 | 132 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1392 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2014 | 122 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 1998 | 456 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 907 | 0.030 |
Why?
|
| Fibrin | 1 | 1994 | 82 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 67 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2018 | 560 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 1996 | 310 | 0.030 |
Why?
|
| Stroke Volume | 2 | 2010 | 544 | 0.030 |
Why?
|
| Bone and Bones | 2 | 2014 | 606 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 1994 | 76 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2013 | 58 | 0.030 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2013 | 52 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 474 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 1994 | 120 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 100 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 304 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2518 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2000 | 922 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 742 | 0.030 |
Why?
|
| Tamoxifen | 3 | 2005 | 875 | 0.030 |
Why?
|
| DNA, Superhelical | 1 | 2013 | 28 | 0.030 |
Why?
|
| HLA-DR Antigens | 2 | 2006 | 184 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 631 | 0.030 |
Why?
|
| Cell Count | 3 | 2004 | 513 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 71 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 366 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2012 | 92 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 191 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 172 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2014 | 255 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 1997 | 596 | 0.030 |
Why?
|
| WT1 Proteins | 1 | 2013 | 107 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2016 | 314 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2012 | 12 | 0.030 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2012 | 12 | 0.030 |
Why?
|
| Research Design | 1 | 2000 | 1569 | 0.030 |
Why?
|
| Bacteria | 1 | 2017 | 653 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 135 | 0.020 |
Why?
|
| Transcriptome | 1 | 2021 | 1960 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 402 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2016 | 632 | 0.020 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2011 | 35 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 667 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2184 | 0.020 |
Why?
|
| Lipids | 1 | 1995 | 654 | 0.020 |
Why?
|
| Lymphography | 1 | 2011 | 50 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1991 | 67 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 183 | 0.020 |
Why?
|
| Cell Communication | 1 | 2014 | 512 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2012 | 1185 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 200 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2012 | 199 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 306 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 149 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2012 | 471 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2012 | 498 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1234 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1991 | 120 | 0.020 |
Why?
|
| Cell Cycle | 2 | 2013 | 2137 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 337 | 0.020 |
Why?
|
| Logistic Models | 2 | 2014 | 3448 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 152 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 2010 | 15 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 613 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 2010 | 30 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 121 | 0.020 |
Why?
|
| Drug Resistance | 2 | 2005 | 610 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 119 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 799 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 311 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2010 | 73 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 1134 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2012 | 273 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 1994 | 616 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 138 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 470 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 40 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1137 | 0.020 |
Why?
|
| Clone Cells | 3 | 1999 | 591 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2010 | 39 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 671 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 587 | 0.020 |
Why?
|
| Isoantigens | 1 | 2009 | 66 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 678 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2009 | 18 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 825 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 1006 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 185 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2009 | 47 | 0.020 |
Why?
|
| North America | 1 | 2010 | 338 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2023 | 5440 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 2003 | 824 | 0.020 |
Why?
|
| Infliximab | 1 | 2009 | 138 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2009 | 109 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 549 | 0.020 |
Why?
|
| Hygromycin B | 1 | 2008 | 8 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2009 | 79 | 0.020 |
Why?
|
| Genes, Synthetic | 1 | 2008 | 30 | 0.020 |
Why?
|
| Breast | 1 | 1996 | 1370 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 158 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 686 | 0.020 |
Why?
|
| Primates | 1 | 2009 | 128 | 0.020 |
Why?
|
| Cinnamates | 1 | 2008 | 29 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2009 | 139 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 634 | 0.020 |
Why?
|
| Receptor, EphA4 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 772 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 440 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 345 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 2165 | 0.020 |
Why?
|
| Phenotype | 2 | 2010 | 6516 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 526 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1246 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2008 | 143 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 105 | 0.020 |
Why?
|
| Codon | 1 | 2008 | 261 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2007 | 8 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2016 | 1697 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 4134 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 144 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2008 | 132 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 589 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 602 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1991 | 767 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2472 | 0.020 |
Why?
|
| Mouthwashes | 1 | 2007 | 42 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2011 | 3078 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2009 | 713 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1607 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2007 | 78 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 258 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2008 | 929 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 730 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2359 | 0.020 |
Why?
|
| Carcinogens, Environmental | 1 | 1986 | 27 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 242 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2929 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2007 | 117 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 404 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 1013 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 883 | 0.020 |
Why?
|
| Glucose | 1 | 2012 | 1220 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 1570 | 0.020 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2006 | 51 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4645 | 0.020 |
Why?
|
| Echinocandins | 1 | 2007 | 134 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2007 | 104 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1525 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 5437 | 0.020 |
Why?
|
| Platelet Count | 2 | 2002 | 492 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 2100 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 727 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1228 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2006 | 186 | 0.020 |
Why?
|
| Imidazoles | 1 | 2011 | 1064 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 224 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 296 | 0.020 |
Why?
|
| Fever | 1 | 1988 | 521 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 170 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1042 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 1582 | 0.010 |
Why?
|
| DNA | 3 | 1998 | 3051 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2005 | 134 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3604 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 283 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3109 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3341 | 0.010 |
Why?
|
| Epithelial Cells | 2 | 2005 | 1875 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2005 | 852 | 0.010 |
Why?
|
| Dasatinib | 1 | 2007 | 881 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1558 | 0.010 |
Why?
|
| Oncogenes | 1 | 1986 | 700 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2006 | 684 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 1610 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 2002 | 17 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2002 | 33 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 151 | 0.010 |
Why?
|
| Aging | 1 | 2010 | 1550 | 0.010 |
Why?
|
| Sheep | 1 | 2002 | 275 | 0.010 |
Why?
|
| Pregnancy | 3 | 2002 | 8125 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 365 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 743 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 210 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2002 | 292 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 4001 | 0.010 |
Why?
|
| Taxoids | 1 | 2005 | 1015 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2008 | 4329 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 480 | 0.010 |
Why?
|
| X-Ray Therapy | 1 | 2000 | 6 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1274 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2010 | 2399 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 841 | 0.010 |
Why?
|
| Prochlorperazine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2004 | 799 | 0.010 |
Why?
|
| Ondansetron | 1 | 1999 | 39 | 0.010 |
Why?
|
| Lorazepam | 1 | 1999 | 40 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1999 | 35 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 190 | 0.010 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1998 | 21 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1999 | 167 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1999 | 188 | 0.010 |
Why?
|
| Mastectomy | 1 | 2005 | 1553 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 2221 | 0.010 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1999 | 114 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1998 | 75 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1997 | 33 | 0.010 |
Why?
|
| Globins | 1 | 1998 | 80 | 0.010 |
Why?
|
| Centrifugation | 1 | 1997 | 65 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 140 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1999 | 155 | 0.010 |
Why?
|
| Gentamicins | 1 | 1997 | 111 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1997 | 255 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 366 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 1999 | 214 | 0.010 |
Why?
|
| Colorado | 1 | 1996 | 26 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 1999 | 276 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2170 | 0.010 |
Why?
|
| Electrolytes | 1 | 1996 | 63 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1986 | 4831 | 0.010 |
Why?
|
| Species Specificity | 1 | 1997 | 794 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 1997 | 418 | 0.010 |
Why?
|
| Avidin | 1 | 1996 | 23 | 0.010 |
Why?
|
| Cryoprotective Agents | 1 | 1996 | 9 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 170 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1996 | 80 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1996 | 49 | 0.010 |
Why?
|
| Spermine | 1 | 1995 | 25 | 0.010 |
Why?
|
| Cations | 1 | 1995 | 59 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 506 | 0.010 |
Why?
|
| Biotin | 1 | 1996 | 78 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 1995 | 63 | 0.010 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1995 | 67 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1991 | 5591 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1996 | 69 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 2178 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1996 | 318 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 3485 | 0.010 |
Why?
|
| Creatinine | 1 | 1996 | 529 | 0.010 |
Why?
|
| Body Weight | 1 | 1999 | 1311 | 0.010 |
Why?
|
| Macrophages | 1 | 2000 | 1352 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1996 | 228 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1994 | 201 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1994 | 445 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1995 | 476 | 0.010 |
Why?
|
| Tachycardia, Sinus | 1 | 1991 | 12 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1991 | 150 | 0.010 |
Why?
|
| Cell Migration Inhibition | 1 | 1990 | 16 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1994 | 517 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1990 | 263 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1990 | 419 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 1121 | 0.000 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1994 | 1229 | 0.000 |
Why?
|
| Organoplatinum Compounds | 1 | 1990 | 704 | 0.000 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1991 | 690 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1991 | 1155 | 0.000 |
Why?
|
| Carcinoma | 1 | 1991 | 2609 | 0.000 |
Why?
|
| Sarcoma | 1 | 1989 | 1838 | 0.000 |
Why?
|